Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign
- 25 June 2010
- journal article
- review article
- Published by Wiley in Acta Paediatrica
- Vol. 99 (11) , 1609-1614
- https://doi.org/10.1111/j.1651-2227.2010.01908.x
Abstract
The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies. While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed.Keywords
This publication has 49 references indexed in Scilit:
- Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006Vaccine, 2009
- The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in CanadaThe Pediatric Infectious Disease Journal, 2009
- Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination EraClinical and Vaccine Immunology, 2008
- Seroprotection against serogroup C meningococcal diseaseBMJ, 2008
- Population-Based Analysis of Meningococcal Disease Mortality in the United StatesThe Pediatric Infectious Disease Journal, 2006
- Epidemiology of invasive meningococcal disease in France in 2003Eurosurveillance, 2005
- The Future of Meningococcal VaccinesThe Pediatric Infectious Disease Journal, 2005
- Meningococcal polysaccharide–protein conjugate vaccinesThe Lancet Infectious Diseases, 2005
- Effectiveness of a Mass Immunization Campaign Using Serogroup C Meningococcal Conjugate VaccinePublished by American Medical Association (AMA) ,2004
- Serogroup W-135 Meningococcal Disease during the Hajj, 2000Emerging Infectious Diseases, 2003